Leaders in Life Sciences

By: Dr. Kesha Chauhan MD
Listen for free

  • Summary

  • The Leaders in Life Sciences podcast features daily news, strategies, interviews with healthcare professionals, and life science executives. This show is for commercial and medical leaders who want to stay up to date and inspired in their daily work.

    Hosted on Acast. See acast.com/privacy for more information.
    Dr. Kesha Chauhan, MD
    Show more Show less
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2
Episodes
  • #14: Citius Oncology's LYMPHIR™ Launch Strategy

    #14: Citius Oncology's LYMPHIR™ Launch Strategy
    Jan 10 2025
    Citius Oncology is preparing to launch LYMPHIR™, a novel treatment for cutaneous T-cell lymphoma (CTCL), and is simultaneously exploring strategic options to maximize its market impact. These options include partnerships and acquisitions to bolster its position within the $400 million CTCL market. The company is focusing on a targeted launch strategy that includes patient support programs and securing international licensing agreements. Their aim is to provide patients with a much-needed therapy while increasing shareholder value. This launch follows years of development and regulatory hurdles.

    Hosted on Acast. See acast.com/privacy for more information.
    Show more Show less
    3 mins
  • #13 : Rybrevant & Lazcluze: A New Era in Lung Cancer Treatment

    #13 : Rybrevant & Lazcluze: A New Era in Lung Cancer Treatment
    Jan 10 2025
    Johnson & Johnson's Rybrevant and Lazcluze drug combination shows significant improvement in overall survival for patients with EGFR-mutated non-small cell lung cancer compared to the current standard treatment, Tagrisso. This new treatment targets a resistance pathway, offering a potential lifeline for many patients, although it requires infusions and has potential side effects. Full trial results are forthcoming, and the company anticipates substantial sales. The development highlights advances in precision medicine for lung cancer.

    Hosted on Acast. See acast.com/privacy for more information.
    Show more Show less
    17 mins
  • #12: What You need to know about Ozempic and Weight Loss

    #12: What You need to know about Ozempic and Weight Loss
    Jan 9 2025
    This podcast episode discusses Ozempic (semaglutide), a GLP-1 receptor agonist initially used for type 2 diabetes, now gaining popularity for weight loss. The episode details its mechanism of action, effectiveness (showing up to 15% weight loss in trials but with caveats regarding individual responses and potential for weight regain), safety (including common and rare side effects), ethical considerations (addressing societal pressures and the need for holistic care), and cost (highlighting affordability issues and the need for equitable access). The podcast aims to inform healthcare professionals and the public about the drug's benefits, limitations, and broader implications.

    Hosted on Acast. See acast.com/privacy for more information.
    Show more Show less
    20 mins

What listeners say about Leaders in Life Sciences

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available